Navigation Links
DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
Date:10/1/2007

MUNICH, Germany, October 1 /PRNewswire/ --

- New Product Under Development for the Treatment of High Blood Pressure

- Approval Requested in 28 European Countries

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe(1). Amlodipin is one of the most frequently used calcium antagonists in many European countries.

"Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure. The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy," says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully," continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japan
'/>"/>

SOURCE DAIICHI SANKYO EUROPE GmbH
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
2. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
3. A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
4. Merge launches diagnostic mammography workstation in Europe
5. Mirus granted European patent for gene therapy
6. Johnson Controls to expand in Europe
7. Innovation thrives in Europe
8. Info security group announces first Eastern European chapter
9. EMD Biosciences partners with European biotech company
10. Third Wave lands European distribution deal, reports high earnings
11. Third Wave seeks approval of Cystic Fibrosis test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 WORMS, GERMANY – ... Co. (NYSE: GRA) announces that its manufacturing facility ... (GMP) certification from EXCiPACT™, an independent organization that ... , All three Grace facilities that ... excipient silica gels have now received GMP certification, ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May ... QIAGEN Clinical Insight ® ... Genvarianten und die Erstellung dazugehöriger Berichte; Vorstellung ...     QIAGEN N.V. (NASDAQ: ... heute die Markteinführung von QIAGEN Clinical Insight ...
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)... , May 26, 2015  Alere Inc. (NYSE: ALR ... its failure to timely file its Quarterly Report on Form ... "Form 10-Q"), it has received a notice from the New ... in compliance with the NYSE,s continued listing requirements under the ... Listed Company Manual. The reason for the ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... , NEW HAVEN, Conn., Sept. ... discovery, development and commercialization of novel drugs for the treatment ... been appointed to the Company,s Board of Directors, succeeding Joseph ... Zook is President of MedImmune, Chief Executive Officer of AstraZeneca ...
... , CHENGDU, China, Sept. ... TPI ), a manufacturer and supplier ... its new,production facility obtained the Good Manufacturing Practices ... Food and Drug,Administration ("SFDA") in China. , ...
... VIENNA, Va., Sept. 16 CEL-SCI Corporation ... and therapeutics for the prevention and treatment of infectious diseases ... Food and Drug Administration (FDA) has indicated that the Company ... effect of its investigational LEAPS-H1N1 treatment on the white blood ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 3Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility 2Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... from the ARC Centre of Excellence for Coral Reef ... science to help solve some of the world,s biggest ... science fellow at the ARC CoECRS, holds a joint ... University in the USA. Dr Hicks says more ...
... WEST LAFAYETTE, Ind. Researchers have discovered a tube-shaped structure ... deliver its DNA during the infection process and then dissolves ... mechanism in the phiX174 virus, which attacks E. coli ... bacteria, is in a class of viruses that do not ...
... by scientists could help combat the spread of sleeping sickness. ... to communicate with one another could help limit the spread of ... could be designed to disrupt the flow of messages sent between ... disrupts sleep patterns is transmitted by the bite of the ...
Cached Biology News:Linking social science and ecology to solve the world's environmental problems 2Virus grows tube to insert DNA during infection then sheds it 2
Guanine nucleotide-binding protein G(k), alpha subunit...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
... P7 D7 F5] to RYK ( ... Antigen: Synthetic ... to amino acids 462 - 475 ... Gene ID: 6259 ...
DAP12 Market Segment: Protein Kinases...
Biology Products: